Stock VIR VIR BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
8.23 USD +7.86% Intraday chart for Vir Biotechnology, Inc. +3.52% -18.19%
Apr. 26 Cytokinetics Appoints Sung Lee as CFO MT
Apr. 18 Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
BU
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
BU
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
AQ
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
BU
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
AQ
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
BU
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
BU
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
BU
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
BU
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
BU
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
BU
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
BU
Vir Biotechnology Ranked The Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500
AQ
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
BU
Vir Biotechnology : Termination of Material Agreement - Form 8-K
PU
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
BU
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
BU
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
GL
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD s The Liver Meeting 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIR Stock
  4. News Vir Biotechnology, Inc.
  5. Press Releases